For more than a decade, a prevailing hypothesis in research related to arterial disease has been that circulating endothelial progenitor cells (EPC) provide protection by their innate ability to replace dysfunctional or damaged endothelium. This paradigm has led to extensive investigation of EPCs in the hope of finding therapeutic targets to control their homing and differentiation. However from the very beginning, the nomenclature and the phenotype of EPCs have been subject to controversy and there are currently no specific markers that can unambiguously identify these cells. Moreover, many of the initial observations that EPCs differentiate to endothelial cells in the course of arterial disease have been criticized for methodological problems. The present review discusses the contrasting experimental evidence as to the role of EPCs in contributing to relining of the endothelium and highlights some of the methodological pitfalls and terminological ambiguities that confuse the field.
INTRODUCTION
The healthy endothelium forms a continuous lining of the vascular system that controls the passage of nutrients and oxygen from the blood into tissues, serves removal of cellular and metabolic waste products, and regulates arterial reactivity through synthesis and release of vasoactive molecules. 1 The basal rate of endothelial cell (EC) proliferation in healthy blood vessels is low but certain regions display a higher rate. 2 Moreover, EC proliferation increases with age and the presence of cardiovascular risk factors. 3 Common for cardiovascular diseases is the loss of normal endothelial function. Prolonged or exaggerated endothelial activation leads to dysfunction and loss of integrity with apoptosis and necrosis. 1, 4 At the atherosclerosis-prone regions of the apolipoprotein E deficient (apoE -/-) mouse, for example, endothelial turnover rate and proliferation is increased early before the development of atherosclerotic plaques. 5 The means whereby the uninterrupted endothelial lining is maintained and regenerated have been debated for a long time (Figure 1 ). In the mid-1900's, several experiments showed that regeneration of damaged endothelium involves EC mitosis. 6, 7 However, other investigators also reported that the endothelium may be derived from other types of cells, including circulating cells in the blood and undifferentiated cells from the subendothelial space. 8 A number of careful studies in the 1970s further supported the dominant role of local EC mitosis and migration in endothelial regeneration after vascular damage, 3, 9, 10 although they provided little information concerning the actual mechanisms that control the movement and proliferation of ECs at injury sites. 11 Additionally, it was shown that small areas of endothelial injury can be repaired solely through EC migration while larger areas of injury are repaired by both proliferation and migration. 9, 12 These findings are in line with indirect evidence obtained in wound healing assays which supports the role of EC proliferation and migration in endothelial repair. 13 Moreover, pathological processes that cause damage to the endothelium can also cause detachment of ECs resulting in a very low number of circulating mature ECs in the bloodstream which might participate in endothelial repair. 14 None of these studies, however, were able to determine whether local proliferation is the only mechanism underlying EC renewal and regeneration.
In a landmark study, Asahara and colleagues 13 isolated putative endothelial progenitor cells (EPC) from the peripheral blood. During short-term culturing, some of these CD34
+ mononuclear blood cells acquired endothelial-like characteristics, and they homed to sites of angiogenesis when injected intravenously into animals with hind limb ischemia. The foundation for research in EPC-mediated repair of the endothelium was laid (Figure 1 ).
During the last decade, numerous studies have undertaken to define the role of EPCs in vascular disease as well as their potential use as a biomarker of cardiovascular disorders.
However, attempts to identify and describe EPCs and their biological properties have yielded conflicting results. As discussed in the present review, much of the controversy may be fostered by inconsistent terminology and common methodological pitfalls.
ORIGIN AND CHARACTERIZATION OF EPCS
EPCs can reside in the bone marrow (BM), the peripheral blood, the vascular adventitia and/or the endothelium itself. [14] [15] [16] Their identification and characterization has been based on a variety of techniques that fall roughly into two categories: flow cytometric assays for cell surface markers and cell culture assays. Asahara 
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Based on cell culture assays, two distinct EPC phenotypes derived from human peripheral blood mononuclear cells have been described. 22 When seeded in culture dishes, colonies of cells with an elongated and spindle shape were observed similar to that of the EPCs first reported by Asahara and colleagues 13 . These cells die within four weeks and were called "early" EPCs in contrast to a cell population displaying an endothelial-like cobblestone shape after two to three weeks, surviving up to twelve weeks and named endothelial colony forming cells (ECFCs) or "late" EPCs. 23 The rare Using flow cytometry and short-term culture assays to measure EPC numbers, similar correlations have been obtained between reduced EPC numbers and the extent of atherosclerosis in other vascular beds than the coronaries, 34 allograft vasculopathy in transplanted hearts, 33 and diffuse in-stent restenosis after percutaneous coronary intervention (PCI). 35 By contrast, Güven and colleagues reported that the number of EPCs was actually increased among patients with significant CAD when EPCs were defined by their ability to give rise to endothelial-cell like colonies during long-term culture (late EPCs). 36 Stem cells usually exist in a quiescent state but start to differentiate and to be mobilized into the systemic circulation upon specific stimulation. For example, putative EPCs can be mobilized in patients with vascular diseases by granulocyte-colony stimulating factor, statins or by exercise. 37 Whether the associations between EPC number and cardiovascular disease reflect alterations in consumption rate or regulation of the release of putative EPCs is unknown.
EPCS AND CARDIOVASCULAR DISEASE

IN VIVO EVIDENCE FOR ENDOTHELIAL CELL ORIGIN
Before classifying cells as EPCs, it is essential to validate their homing and differentiation potential in vivo. The ability to produce cells with endothelial characteristics in vitro is indicative, but the capacity to incorporate into an endothelial lining and conduct EC functions is a far more stringent criterion which cannot be tested outside the living organism. If EPCs exist and undertake physiologically relevant repair of the endothelium, it should be possible to detect their contribution by labelling circulating cells with a genetic tracking marker and analyse their fate using specific markers for phenotype and high-resolution microscopy of the blood vessel wall ( Figure   2 ). 38, 39 This approach also has the advantage that it bypasses the errors involved with isolation of EPCs, if they exist, and the confusion regarding appropriate phenotypic markers of these cells.
EPCS IN MODELS OF ARTERIAL DISEASE
Most arterial diseases involve injury to or death of ECs. Circulating EPCs may contribute to the generation of microvascular ECs at sites of neovascularization, 13, 40 and to relining of the endothelium after various kinds of arterial injuries, including mechanical removal, [41] [42] [43] and allograft vasculopathy, 41, 44, 45 as well as to vein graft atherosclerosis. 46 Although atherosclerosis is by far the most important arterial disease worldwide, only few studies have been conducted on the role of putative EPCs in the EC turnover associated with this disease.
EPCs in atherosclerosis
Only indirect evidence exists supporting the prevailing understanding that circulating
EPCs provide protection against atherosclerosis by their ability to replace dysfunctional ECs. 5, 47 The few studies in which atherosclerotic mice received BM-or blood-derived cells assumed to contain EPCs intravenously yielded discrepant results. Thus, Silvestre et al. 48 and George et al. 49 reported that transplantation of BM-derived cells accelerated atherosclerosis while Zoll and colleagues 50 found that injection of EPCs had no effect on the development of the disease. In yet another study, the intravenous injection of BMderived progenitors from young non-atherosclerotic into mature atherosclerotic apoE -/-mice exerted a vascular protective effect. 51 Some of the injected cells adhered to the surface of atherosclerosis-prone areas of the aorta, an observation which lead to the suggestion that they may reduce atherosclerosis by replacing senescent ECs in plaques. 51 Others, however, observed that the injection of fluorescently-labeled BM-and spleenderived EPCs in apoE -/-mice, resulted in the predominant accumulation of these cells within the lipid core of the plaques and not within the endothelium. 49 In a transgenic TIE2-lacZ mouse model of vein graft atherosclerosis expressing β-galactosidase positive (β-gal + ) in ECs, the endothelium was partly repaired by BMderived EPCs. 46 In vein grafts from TIE2-LacZ mice transplanted into the carotid artery of wild-type mice, the number of β-gal + cells was reduced markedly while such cells were evenly distributed on the surface of wild-type vein segments when transplanted into TIE2-LacZ mice. 46 Moreover, β-gal + cells were seen on wild-type veins transplanted into mice carrying BM cells from TIE2-LacZ mice. 46 These data are in line with the observation that, in areas prone to lesion development in apoE -/-mice transplanted with BM from TIE2-lacZ mice, 3% to 4% of cells displaying progenitor markers were β-gal
Only one study so far has analyzed the origin of the plaque endothelium during the actual development of atherosclerosis in hyperlipidemic apoE -/-mice. Not a single circulatory EPC-derived EC was present at the plaque surface. 38 This finding was further corroborated by studies of endothelial regeneration after mechanical injury to advanced plaques in old apoE -/-mice, where the regenerated endothelium was derived exclusively from the local blood vessel wall, presumably through proliferation of flanking ECs (Figure 2) . 38 Plaque neovascularization may contribute to plaque growth and increase plaque vulnerability, 52, 53 but due to the lack of animal models featuring plaque neovessels, not much are known about the contribution of EPCs to this process.
EPCs in allograft vasculopathy
In 2002 Quaini and colleagues 54 reported that recipient-derived cardiomyocytes, smooth muscle cells and ECs were common in sex-mismatched (female-to-male) heart transplants. Multiple studies have been conducted to study this phenomenon in simplified rodent models where vessel allografts are transplanted into the arterial system of recipients without immunosuppression to protect the donor cells. In these systems, the endothelium of the allograft efficiently regenerates with recipient-derived cells. The hypothesis that the majority of these recipient-derived cells originates from circulating
EPCs that home and differentiate into mature ECs in the allografts has attracted particular interest. 55, 56 Using a mouse model in which the expression of β-gal was regulated by the endothelial-specific TIE2 promoter, Hu et al. 45 observed that ECs of neointimal lesions in allografts of aortic segments are derived from β-gal + circulating EPCs with approximately 30% of ECs being of BM origin. 45 By contrast, Hillebrands and colleagues 44 reported that the contribution of BM-derived EPCs was only minimal (1 to 3%) when investigating the origin of ECs by performing orthotopic aortic allografting in BM-chimeric recipient rats; they did, however, not determine the potential contribution from non-BM-derived EPCs. Taken in conjunction, these studies point to a contribution of non-BM-and BM-derived EPCs in transplant atherosclerosis rather than ECs from the nearby blood vessel wall, as inferred mainly from the absence of observable inward migration fronts of ECs at selected early time points after allografting. 44, 45 By contrast, the majority of the reported data favors the view that ECs in allografts are derived from migrating ECs from the flanking vasculature.
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When an allografted blood vessel or heart is interpositioned in a recipient, it is not obvious to ascertain whether cells originate, 
EPCs in endothelial regeneration
Re-endothelialization after mechanical vascular injury, including PCI, is essential for inhibition of neointima formation and restoration of vascular homeostasis. 57, 58 Several studies in experimental models have concluded that circulating EPCs may be involved in this process. Using a mechanical arterial injury in TIE2-GFP + transgenic mice, to establish whether circulating non-BM-derived EPCs or the nearby healthy endothelium contributed to EC regeneration, revealed that endothelial regeneration does not involve homing and differentiation of circulating EPCs into ECs. 65 Instead, the endothelium regenerated by 
EPCs and neovascularization
Circulating cells have been reported to incorporate into and facilitate neovascularization of ischemic tissues. 40, 66 In ischemic hindlimbs of mice transplanted with BM cells expressing lacZ under the regulation of an EC lineage-specific promoter (Flk-1 or Tie-2), Asahara et al. found lacZ + cells to be incorporated into capillaries between skeletal myocytes. 40 Moreover, after ligation of the left coronary artery, EPCs were found to be incorporated into foci of neovascularization at the border of the infarct. 40 Circulating
EPCs have also been reported to contribute to the endothelial lining of microvessels in wound healing, 67 tumor growth, 40 and corneal neovascularization. 68 The observation that BM-derived EPCs may facilitate and incorporate into neovessels in ischemic muscle offers hope that one could harness this mechanism to treat chronic refractory myocardial ischemia or improve functional recovery after myocardial infarction. 69, 70 Using a variety of cell sources and delivery strategies, the effect of transplanting autologous BM-derived cells to the suffering myocardium has been tested in clinical studies. Some of these, but not all, 69 have shown significant improvements in specified endpoints such as angina frequency or exercise tolerance. 71 Whether the positive effects, when observed, involve stable integration of the transplanted cells and differentiation to
ECs has been debated. Putative EPCs have been shown to be able to facilitate neovascularization through secretion of paracrine factors 66, 72, 73 ; e.g. injecting EPCconditioned medium alone into a rat model of chronic hindlimb ischemia increased capillary density, blood flow and muscle performance significantly. 73 The key methodological issues in the EPC field are probably not different from those initiating other controversies in the progenitor cell field being rooted in the failure to reach clear single-cell resolution, and in the use of unspecific cell markers or detection systems. 38, 80 Detection of EPC contribution to the endothelium has been based on models in which a population of cells, e.g. BM or circulating cells, assumed to be enriched for EPCs, is tagged with a transgene encoding a reporter molecule, such as eGFP or -gal.
Incorporation of tagged cells in the endothelial lining and their expression of characteristic endothelial proteins is the criterion used to detect EPC-derived arterial ECs.
In many vascular diseases, homing of BM-derived cells is an inherent part of the pathophysiological process. After vascular injury, hematopoietic cells may transiently cover the denuded area before being replaced by regenerated endothelium 16 , and such cells may easily be mistaken for BM-derived ECs early after injury. Furthermore, in atherosclerosis, there is an ongoing passage of BM-derived inflammatory cells through the endothelial layer. Moreover, some of these cells may reside in the subendothelial space in close proximity to ECs. Reporter transgenes driven by the endothelial-specific angiopoietin receptor TIE2
promoter have often been used to track BM derived ECs. 5, 40, 42, 46, 59, 86, 87 The use of a reporter molecule that is only expressed in cells of the endothelial lineage obviates the need for single-cell resolution, but puts great dependence on the endothelial specificity of the promoter. However, a subpopulation of monocytes that circulates in the peripheral blood and is recruited to sites of angiogenesis and in regenerating tissues also expresses TIE2. 88, 89 These cells localize in close proximity to ECs and can therefore easily be mistaken for BM-derived ECs.
EPC OR ONLY PUTATIVE EPC
As said above, in most arterial diseases inflammation takes place, in which mobilization, circulation, homing, and local differentiation of BM-derived leukocytes play important roles in disease progression. Since many EPC populations contain monocytes, it therefore can be expected that when injecting putative EPC populations into animals some of these cells will home to sites of vascular damage. Dil-Ac-LDL uptake and lectin binding together with endothelial marker expression is the phenotypic profile that is commonly Noticeably, monocytes already express most tested endothelial genes and proteins at even higher levels than the so-called EPCs, and colony-forming unit ECs (CFU-EC) formation is strictly dependent on monocyte presence. 77 The putative EPC population of colony-forming mononuclear cells in human peripheral blood, similar to those described by Asahara and colleagues in mice 13, 40 , later appeared to be composed mainly of inflammatory and immune mononuclear cells rather than true EPCs 20, 26, 76, 77, 91, 92 and such cells home to sites of arterial injury and atherosclerosis.
PARACRINE EFFECT
An alternative explanation for the association between EPCs and endothelial regeneration may be that some of the cells contained in the "EPC" cell populations exert proangiogenic paracrine effects without actually differentiating into ECs. 20, 81, 89, 91 They may adhere and migrate through the endothelium into the blood vessel wall and there release growth factors and chemokines that stimulate endothelial regeneration by resident ECs.
Putative "EPCs" obtained in short-term culture assays (early EPCs) express monocyte/macrophage markers and secrete multiple potent angiogenic growth factors 76 that enhance EC migration 93 and protect against oxidative stress-induced apoptosis. 94 Consistent with such paracrine function, serial injections of conditioned media harvested from peripheral blood-derived EPCs into an ischemic hind limb ameliorated local perfusion by promoting neovascularisation and vascular maturation. integrating into the endothelium. 89 Induced apoptosis of these cells through activation of a suicide gene blocked tumor angiogenesis indicating that they stimulate angiogenesis though paracrine signaling. 89 The term EPC was initially used in the literally correct way for immature precursor cells capable of differentiating into mature ECs in vivo. 13, [40] [41] [42] [43] [44] 46 Now the term has gradually been redefined to include circulating angiogenic cells without an endothelial fate. Thus, an alternative explanation for the conflicting results reported in the literature could be due to paracrine signaling to local ECs by blood -derived pro-angiogenic cells. 79 However, to avoid confusion, the literally correct definition of a progenitor cell as an immature precursor cell capable of differentiating into a mature cell type in vivo should be retained.
CONCLUSION
After more than ten years of enthusiastic research in EPC biology, researchers worldwide 
